Thrombosis Research
IF
3.94
Papers
16.4k
Papers 10,000
1 page of 1,000 pages (10k results)
Newest
#1Jie Li (Capital Medical University)
#2Jiawen Yi (Capital Medical University)H-Index: 2
Last. Yuhui Zhang (Capital Medical University)H-Index: 6
view all 10 authors...
INTRODUCTION The risk of venous thromboembolism (VTE) varies among tumour types, and different cancer type-specific risks for VTE prediction remain undefined. We aimed to establish a prediction model for non-small lung cancer (NSCLC)-associated VTE. MATERIALS AND METHODS We analysed data from a prospective cohort of patients with newly diagnosed NSCLC. We then developed a VTE risk prediction model using data of patients who were recruited from 2013 to 2017 (n = 602, development cohort) and valid...
Source
#1Allen Li (U of O: University of Ottawa)H-Index: 4
#2Willem Brandt (Ottawa Hospital Research Institute)
Last. Marc Carrier (Ottawa Hospital Research Institute)H-Index: 60
view all 8 authors...
BACKGROUND Venous thromboembolism (VTE) is a leading cause of mortality in patients with cancer and is associated with significant morbidity and healthcare expenditure. The risk of VTE is increased following the insertion of a central venous catheter (CVC) for chemotherapy delivery and supportive care. The risks and benefits of primary thromboprophylaxis in patients with cancer and CVC are unclear. OBJECTIVE We sought to assess the rates of VTE and bleeding complications and to determine the eff...
Source
#1Rebecca Swayngim (Denver Health Medical Center)H-Index: 2
#2Candice Preslaski (Denver Health Medical Center)H-Index: 6
Last. Jacob T. Beyer (Denver Health Medical Center)H-Index: 3
view all 4 authors...
Abstract null null Introduction null Continuous intravenous unfractionated heparin (UFH) is a mainstay of therapeutic anticoagulation in the acute setting. The two most common laboratory tests for monitoring UFH are the activated partial thromboplastin time (aPTT) and antifactor Xa (anti-Xa) heparin assay. We reviewed the available evidence to evaluate if the choice of monitoring test for UFH therapy is associated with a difference in the clinical outcomes of bleeding, thrombosis, or mortality. ...
Source
#1Spencer Davis (Intermountain Medical Center)
#2Stephanie Chauv (Intermountain Medical Center)H-Index: 2
Last. Gabriel V. Fontaine (Intermountain Medical Center)H-Index: 7
view all 6 authors...
Abstract null null Background & purpose null 4-factor prothrombin complex concentrate (4FPCC) is used off-label for factor Xa (FXa) inhibitor-associated intracranial hemorrhage (ICH). Guideline recommendations provide various 4FPCC dosing regimens for FXa inhibitor reversal in this setting. We evaluated 4FPCC weight-based dosing and outcomes in FXa inhibitor-associated ICH. null null null Methods null We conducted a multi-center, retrospective, cohort study of ICH patients between July 2017 and ...
Source
#1Erzsébet Tóth (Semmelweis University)H-Index: 8
#2László Beinrohr (Semmelweis University)
Last. Krasimir Kolev (Semmelweis University)H-Index: 21
view all 12 authors...
Abstract null null Introduction null The composition of thrombi determines their structure, mechanical stability, susceptibility to lysis, and consequently, the clinical outcome in coronary artery disease (CAD), acute ischemic stroke (AIS), and peripheral artery disease (PAD). Fibrin forms the primary matrix of thrombi intertwined with DNA, derived from neutrophil extracellular traps (NETs), and von Willebrand factor (VWF) bridging DNA and platelets. Here we examined the relative content of fibr...
Source
#1John K. Bartoli-Abdou ('KCL': King's College London)H-Index: 3
#2Jignesh P. Patel (University of Cambridge)H-Index: 17
Last. Vivian Auyeung ('KCL': King's College London)H-Index: 12
view all 8 authors...
AIMS Switching non-adherent patients prescribed anticoagulant treatment to a regime with less monitoring could lead to significant non-adherence. Health beliefs are known to influence medication adherence; however, the extent of this influence is unknown in patients switched from vitamin-K antagonists (VKAs) to direct oral anticoagulants (DOACs). This study aimed to determine adherence to long-term therapy in patients switched from VKAs to DOAC due to low time in therapeutic range (TTR) and if a...
Source
#1Thita Chiasakul (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 3
#2Jeffrey I. Zwicker (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 30
Abstract null null Venous thromboembolism (VTE) is a common complication in patients with cancer. Warfarin has largely been replaced by low-molecular-weight heparin (LMWHs) and direct oral anticoagulants (DOACs) as the standard of care in cancer-associated VTE. The survival benefit of these anticoagulants over warfarin in the cancer population was not demonstrated in clinical trials, possibly due to insufficient sample size and limited follow-up duration. There are emerging population-based stud...
Source
#2Judith CatellaH-Index: 2
Last. Laurent Bertoletti (Jean Monnet University)H-Index: 29
view all 10 authors...
Abstract null null Background null Concomitant anticoagulant and antiplatelet therapy increases bleeding risk, but most data are derived from patients with atrial fibrillation. Patients with venous thromboembolism (VTE) may differ. null null null Objective null To study the management of patients diagnosed with acute VTE while receiving antiplatelet treatment. The primary outcome was the number of patients discharged with concomitant therapy. Secondary outcomes were clinically relevant bleeding,...
Source
#1Hanna H. Pitkänen (UH: University of Helsinki)H-Index: 2
#2Annukka Jouppila (UH: University of Helsinki)H-Index: 10
Last. Riitta Lassila (UH: University of Helsinki)H-Index: 35
view all 10 authors...
Abstract null null Background null Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare coagulation disorder reported after administration of COVID-19 adenovirus-vectored vaccines. VITT is mediated by anti-platelet factor 4 (PF4) antibodies activating platelets through the Fcγ-receptor II (FcγRII), and it is associated with strong fibrin turnover. The complement system is involved in several other immunothrombotic entities, but its impact on VITT is not established. null null null Object...
Source
#1Sarah Hanigan (UM: University of Michigan)H-Index: 3
#2Geoffrey D. Barnes (UM: University of Michigan)H-Index: 19
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.